EUVIMEDEUVIMED entdecken
Kohortenstudie

Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study

Pao-Huan Chen, Shang-Ying Tsai iD, Po-Yu Chen, Chun-Hung Pan, Sheng-Siang Su, Chiao-Chicy Chen, Chian-Jue Kuo iD

The British Journal of Psychiatry · 2024-08 · 225 (2) · 328-336

DOI: 10.1192/bjp.2024.85 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The British Journal of Psychiatry, online erschienen am 16.05.2024. Verfasst von Pao-Huan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Taipei Medical University Hospital, Taiwan; Psychiatric Research Center, Taipei Medical University Hospital, Taiwan; and De…. Hauptthemen laut MEDLINE: Schizophrenia, Suicide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Individuals with schizophrenia face high mortality risks. The effects of lipid-modifying agents on this risk remain understudied.

Aim

This study was conducted to investigate the effects of lipid-modifying agents on mortality risk in people with schizophrenia.

Method

This nationwide cohort study collected the data of people with schizophrenia from Taiwan's National Health Insurance Research Database for the period between 1 January 2001 and 31 December 2019. Multivariable Cox proportional hazards regression with a time-dependent model was used to estimate the hazard ratio for mortality associated with each lipid-modifying agent.

Results

This study included 110 300 people with schizophrenia. Of them, 22 528 died (19 754 from natural causes and 1606 from suicide) during the study period, as confirmed using data from Taiwan's national mortality database. The use of lipid-modifying agents was associated with reduced risks of all-cause (adjusted hazard ratio [aHR]:0.37; P < 0.001) and natural (aHR:0.37; P < 0.001) mortality during a 5-year period. Among the lipid-modifying agents, statins and fibrates were associated with reduced risks of all-cause mortality (aHRs:0.37 and 0.39, respectively; P < 0.001 for both) and natural mortality (aHRs: 0.37 and 0.42, respectively; P < 0.001 for both). Notably, although our univariate analysis indicated an association between the use of lipid-modifying agents and a reduced risk of suicide mortality, the multivariate analysis revealed no significant association.

Conclusions

Lipid-modifying agents, particularly statins and fibrates, reduce the risk of mortality in people with schizophrenia. Appropriate use of lipid-modifying agents may bridge the mortality gap between these individuals and the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaSuicideHumansMaleFemaleTaiwanAdultMiddle AgedCause of DeathCohort StudiesHypolipidemic AgentsAgedProportional Hazards Models

Stichwörter der Autor:innen

Schizophreniafibratelipid-modifying agentstandardised mortality ratiostatin

Substanzen

Hypolipidemic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Taipei Medical University Hospital, Taiwan; Psychiatric Research Center, Taipei Medical University Hospital, Taiwan; and Department of Psychiatry, School of Medicine, College of Medicine, Taipe…
  • Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan; and Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.
  • Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan; and Department of Psychology, National Chengchi University, Taiwan.
  • Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.
  • Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan; and Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan.
  • Psychiatric Research Center, Taipei Medical University Hospital, Taiwan; Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taiwan; and Taipei City Psychiatric Center, Taipei C…

ORCID-Profile: Shang-Ying Tsai, Chian-Jue Kuo

Zitieren

APA

Chen, P. H., Tsai, S. Y., Chen, P. Y., Pan, C. H., Su, S. S., Chen, C. C., & Kuo, C. J. (2024). Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study. The British Journal of Psychiatry, 225(2), 328-336. https://doi.org/10.1192/bjp.2024.85

Vancouver

Chen PH, Tsai SY, Chen PY, Pan CH, Su SS, Chen CC, et al. Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study. The British Journal of Psychiatry. 2024;225(2):328-336. doi:10.1192/bjp.2024.85

BibTeX
@article{Chen2024,
  author = {Chen, Pao-Huan and Tsai, Shang-Ying and Chen, Po-Yu and Pan, Chun-Hung and Su, Sheng-Siang and Chen, Chiao-Chicy and Kuo, Chian-Jue},
  title = {Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study},
  journal = {The British Journal of Psychiatry},
  year = {2024},
  volume = {225},
  number = {2},
  pages = {328--336},
  doi = {10.1192/bjp.2024.85}
}
Kostenlos starten →